Asker Healthcare Group Ab · OMXSTO:ASKER
Asker Healthcare Group Ab — Q1 2025 Earnings Presentation
14 slides from Asker Healthcare Group Ab's earnings presentation, May 13, 2025
Slide 1: Steady quarter of profitable growth
Q1 INTERIM REPORT JANUARY – MARCH 2025 Steady quarter of profitable growth Johan Falk CEO Thomas Moss CFO 1
Slide 2: Q1 Highlights
Q1 Highlights JANUARY – MARCH 2025 • Solid momentum in the business ADJ. EBITA GROWTH 17% • Net sales SEK 3,995m, up 16% of which 6% organic • Adj. EBITA increased by 17% to SEK 364m of which 6% organic • Adj. EBITA margin increased to 9.1% (+0.1 p.p) • Two new acquisitions, followed by one more aft
Slide 3: Delivering on our financial targets
+22% +67% Delivering on our Adj. EBITA R/RK (EBITA/NWC) growth per year financial targets LTM outcome TARGET >15% TARGET >50% 9.1% 1.7x Adj. EBITA margin Net Debt/EBITDA* (medium term) TARGET >10% TARGET <2.5x 3 *Adjusted for leases and items affecting comparability
Slide 4: Acquisitions – driving continued international expansion
Acquisitions – driving continued international expansion Annual sales, Month Acquisition Business Area SEKm* Hospital Services February Limited West 800 • 2 new strategic acquisitions Q1 February Mayumana West 60 — adding SEK 860m in sales Healthcare • Continued strengthened position in UK and Decem
Slide 5: Explore an acquisition
Explore an acquisition • Leading product and service provider of medical equipment and related supplies, maintenance and digital health solutions • Serving healthcare providers in Ireland and the UK • Annual sales of SEK 800m Hospital Services Limited • 150 FTE • Track record of building strong Help
Slide 6: Steady growth in net sales and EBITA continued in Q1
Financial performance – Group Steady growth in net sales and EBITA continued in Q1 Amounts in SEKm Q1 2025 YoY Change LTM Full year Adj. EBITA growth (Jan–Mar 2025) 2024/2025 2024 20% Net sales 3,995 16% 15,565 15,025 12% 18% 17% 16% -1% Adj. EBITA 364 17% 1,414 1,362 14% 12% 10% Adj. EBITA margin,
Slide 7: Stable organic net sales performance across the region in Q1
Business Area North Stable organic net sales performance across the region in Q1 Amounts in SEKm Q1 2025 YoY Change LTM Full year Jan–Mar 2025 2024/2025 2024 • Adj. EBITA growth -2% Net sales 1,263 2% 5,431 5,401 ⎯ Organic growth of -3% Adj. EBITA 177 -2% 745 749 ⎯ Acquired growth of 1% ⎯ Exchange r
Slide 8: Strong organic growth in West in Q1
Business Area West Strong organic growth in West in Q1 Amounts in SEKm Q1 2025 YoY Change LTM Full year Jan–Mar 2025 2024/2025 2024 • Adj. EBITA growth 35% Net sales 2,008 19% 7,459 7,145 ⎯ Organic growth of 24% Adj. EBITA 161 35% 587 545 ⎯ Acquired growth of 12% ⎯ Exchange rate effect -1% Adj. EBIT
Slide 9: Q1 performance driven by an active acquisition agenda in Central
Business Area Central Q1 performance driven by an active acquisition agenda in Central Amounts in SEKm Q1 2025 YoY Change LTM Full year Jan–Mar 2025 2024/2025 2024 • Adj. EBITA growth 75% Net sales 725 37% 2,674 2,479 ⎯ Organic growth of 13% Adj. EBITA 54 75% 194 170 ⎯ Acquired growth of 62% ⎯ Excha
Slide 10: Improved R/RK driven by higher EBITA and efficient working capital utilisation
Improved R/RK driven by higher EBITA and efficient working capital utilisation R/RK • R/RK increased by +2.8 p.p. to 66.5% • Continued to maintain high efficiency 100% across all business area 80% 60% 40% 20% 0% Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 R/RK (EBITA/NWC)
Slide 11: Solid financial position enabled acquisitions with maintained low leverage
Solid financial position enabled acquisitions with maintained low leverage Net debt/EBITDA* development Q1 2025 Q1 2024 3x Cash flow from 109 237 operating activities Cash flow for the period 282 -71 • Leverage at end of March 1.7x (2.2x) • Net debt decreased to SEK 2,585m (2,786) 2x ⎯ Driven by EBI
Slide 12: Q1 in summary
Q1 in summary • Solid EBITA growth of 17% • Continued above-market organic growth with strong organic earnings growth in both Central and West • On track with 12 acquisitions in the LTM, combined annual sales of SEK 1.8 billion, including two in Q1 – driving international expansion • Strong balance
Slide 13: Q&A
Q&A
Slide 14: Financial calendar
Financial calendar • Interim report Q2 22 July 2025 • Interim report Q3 6 Nov 2025 • Year-end report 2025 10 Feb 2026 We are health in progress Additional information • Improve patient outcome • Reduce total cost of care Thomas Moss, CFO and Head of IR • Ensure a fair and sustainable Tel: +46 70 219
Asker Healthcare Group — Q1 2025 Earnings Presentation on 6ix